UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
 
NOTIFICATION OF LATE FILING
 
 
 
(Check one):
 
☐ Form 10-K
☐ Form 20-F
☐ Form 11-K
☒ Form 10-Q
☐ Form 10-D
 
 
☐ Form N-CEN
☐ Form N-CSR
 
 
 
 
 
 
 
 
 
 
 
 
For Period Ended:
June 30, 2020
 
 
☐ Transition Report on Form 10-K
 
 
 
 
☐ Transition Report on Form 20-F
 
 
 
 
☐ Transition Report on Form 11-K
 
 
 
 
☐ Transition Report on Form 10-Q
 
 
 
 
For the Transition Period Ended:
 
 
 
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:


 
PART I — REGISTRANT INFORMATION
 
Cellular Biomedicine Group, Inc.
Full Name of Registrant
 
Not Applicable
Former Name if Applicable
 
209 Perry Parkway, Suite 13
Address of Principal Executive Office (Street and Number)
 
Gaithersburg, MD 20877
City, State and Zip Code
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
(a)
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
PART III — NARRATIVE
 
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
Cellular Biomedicine Group, Inc. (“CBMG” or the “Company”) has determined that it is unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020 (the “Form 10-Q”) within the prescribed period without unreasonable effort or expense because it is still finalizing its description of recent developments with regard to subsequent events in the Form 10-Q. The Company anticipates that it will file the Form 10-Q as soon as reasonably possible and within the 5-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.
 
 
 
 
PART IV — OTHER INFORMATION
 
(1)
Name and telephone number of person to contact in regard to this notification
 
Andrew Chan
 
301
 
825-5320
 
(Name)
 
(Area Code)
 
(Telephone Number)
 
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
 
 
 
 
 
 
☒ Yes    ☐ No
 
 
 
 
 
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
 
 
 
 
 
 
☐ Yes    ☒ No
 
 
 
 
 
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
 
Cautionary Note Regarding Forward-Looking Statements
 
This Form 12b-25 contains forward-looking statements, including, without limitation, statements regarding CBMG’s expectations as to the filing of the Form 10-Q and the presentation of subsequent events. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, including risks relating to the impact of the COVID-19 pandemic on our operations. These statements reflect our current views with respect to future events or to our future activities and involve known and unknown risks, uncertainties and other factors which may cause our actual activities, actions or achievements to be materially different from any future activities, actions or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
 
 
 
 
 
Cellular Biomedicine Group, Inc.

(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date
August 10, 2020
 
By
/s/ Andrew Chan
 
 
 
 
Andrew Chan
Chief Legal Officer (General Counsel), 
Corporate Development and Secretary
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cellular Biomedicine Charts.
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cellular Biomedicine Charts.